The COVID Project
The record
- Jurisdiction
- United States (federal); Department of Justice, Drug Enforcement Administration
- Level
- Federal
- Authority
- 21 U.S.C. 821, 822, 823, 871(b); 21 C.F.R. parts 1300, 1301, 1304
- Issued
- 2021-06-28 June 28, 2021
- Effective
- 2021-07-28
- End
- In force (permanent) (read as 2021-09-30)
- In force
- July 28, 2021 to Sept. 30, 2021
- Quarters
- 2021 Q3
2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
- Limitation types
- Health care ordersOther
- Addressees
- DEA-registered narcotic treatment programs
- Functions reached
- CL clinical dispensing
- TR transport
- CB patients
- Collection
- Other federal health agencies AGY-FED-HEALTH-OTHER
Operative words
Under this final rule, an NTP is permitted to dispense narcotic drugs in schedules II-V from a mobile component at location(s) remote from, but within the same State as, the NTP's registered location, for the purpose of maintenance or detoxification treatment. Under this final rule, the NTP does not need to obtain a separate DEA registration for dispensing from the mobile component at a separate location as long as it complies with the requirements of the final rule.
Enforcement
Registration conditions under 21 U.S.C. 823-824; violations subject to 21 U.S.C. 842-843
Notes
Issued during and in response to the pandemic's disruption of in-person dosing; a Q3 2021 instrument changing how opioid treatment programs operated.